Cyngn company logo
CYN NASDAQ

Cyngn

Menlo Park, United States · Founded 2013

Stock Chart

Loading chart data...

Data from Yahoo Finance

Symbol
CYN
Exchange
NASDAQ
Funding
$65M
Employees
51-100

About Cyngn

Cyngn Inc. is a Menlo Park, California-based autonomous vehicle technology company that develops autonomous mobile robots (AMRs) to automate material handling and hauling workflows in industrial settings. Founded in 2013 and publicly traded on NASDAQ (CYN), the company has raised approximately  million in funding. Their Enterprise Autonomy Suite includes DriveMod (autonomous vehicle system), Cyngn Insight (fleet management and analytics), and Cyngn Evolve (AI simulation toolkit). DriveMod technology transforms industry-tested OEM vehicles from manufacturers like Motrec and BYD into self-driving machines capable of hauling up to 12,000 lbs. Key features include 360-degree obstacle and pedestrian tracking, multi-layer collision avoidance that reacts 3x faster than humans, and advanced safety systems with redundancy and emergency controls. The platform requires no specialized infrastructure unlike traditional AGVs, offering flexible and programmable mission capabilities with real-time decision-making. Customers report a 33% boost in productivity, 64% reduction in labor costs, and 18-month average payback period. Notable customers include Pepsi, John Deere, Arauco, NVIDIA, Coats North America, and US Continental. The company holds 23 granted patents and has strategic partnerships with NVIDIA for Isaac Sim integration. Recent achievements include being added as a supply partner to John Deere, demonstrating enterprise-scale validation of their autonomous industrial vehicle technology.

Key Products

DriveMod, Enterprise Autonomy Suite

Company Details

Country
United States
City
Menlo Park
Founded
2013
Type
commercial

Disclaimer: This page is for informational purposes only and should not be considered financial advice. Always conduct your own research and consult with a financial advisor before making investment decisions.